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Human hepatitis B virus (HBV) envelopes contain three distinct glycoproteins called L, M, and S HBsAg. Each is posttransla-
tionally modified to contain N-linked oligosaccharides. N-linked oligosaccharides, after attachment to a polypeptide backbone,
are processed by enzymes within the endoplasmic reticulum (ER). There is uncertainty about what role, if any, these N
glycans and their modification in the ER play in the function of the HBV envelope proteins. By treating hepatoblastoma
cultures which secrete HBV (HepG 2.2.15 cells) with inhibitors of different steps of the glycosylation and glycan modifying
pathway, we provide evidence that glycosylation and the first step in the processing pathway are necessary for virion, but
not subviral particle, secretion. That is, using a highly sensitive immunoprecipitation/polymerase chain reaction system,
enveloped HBV could not be detected in the medium of HepG2.2.15 cells incubated with tunicamycin. However, HBV subviral
particle secretion was not prevented by tunicamycin. Moreover, inhibitors of a-glucosidase I (the first step in the glycan
processing pathway) also prevented virion secretion. Inhibitors of mannose trimming (a later step) and glycolipid synthesis,
did not prevent virion secretion, defining the limits of the glycosylation requirements in secretion. These results demonstrate
a requirement for N-glycosylation and glucosidase processing in the secretion of virions and further distinguish between
the requirements for virion and subviral particle secretion. q 1995 Academic Press, Inc.
Hepatitis B virus (HBV) is the human member of the Although woodchuck and human hepatitis virus enve-
hepadnaviridae, a family of small, enveloped, liver tropic lope proteins are N-glycosylated, the Duck HBV homo-
viruses (reviewed in 26). Productively infected hepato- logues do not appear to contain N-glycan. What role, if
cytes produce subviral, DNA negative, 22-nm particles any, N-glycosylation plays in the morphogenesis of HBV
in vast excess relative to 42-nm DNA containing virions remains unclear. Others have shown that subviral parti-
(reviewed in 12). The reasons for this are not known. All cles are secreted from tunicamycin-treated, HBV produc-
viral particles (virions and subviral forms) contain host- ing cells (25, 28). Since tunicamycin is a potent inhibitor
derived lipid envelopes which are characterized by the of N-linked glycosylation, it was assumed that N-linked
presence of viral envelope glycoproteins. HBV specifies glycosylation was not necessary for HBV secretion. How-
three proteins encoded by the same ‘‘env’’ gene con- ever, those previous studies were limited to an analysis
taining a single continuous 400 codon open reading of subviral particle (and not virion) secretion. Virion and
frame. Translation initiation from alternative start sites subviral particle secretion may involve different host and
within env mRNA result in the three distinct carboxy co- viral functions. Virions are biochemically distinct from
terminal polypeptides called L (large), M (Middle), and subviral particles in that they contain L protein and a
S (small) HBsAg. Virion envelopes contain all three N- nucleocapsid core. Thus, a common secretory strategy
for virions and subviral particles should not be assumed.glycoproteins but subviral envelopes contain almost no
We have shown, for example, that virion, but not subviralL protein (15).
particle, secretion is prevented by inhibitors of the glu-The envelope proteins play an essential role in virion
cose trimming enzyme, glucosidase I (3). Thus, virion andmorphogenesis and secretion. L and S proteins are nec-
subviral particle secretion probably have very differentessary for virion secretion (4, 5, 29), although the role of
sensitivities to glycan processing events. Therefore, al-M is in doubt (5, 10). The current model of virion formation
though subviral particle secretion may not require N-involves nucleocapsids budding into the lumen of the
glycosylation and virion secretion does appear to requireendoplasmic reticulum (ER), after acquiring membranes
glucose trimming, the N-glycosylation requirements ofwhich have been appropriately modified with virion gly-
virion secretion have not yet been determined.coproteins (11, 19).
The N-glycosylation pathway in eukaryotic cells has
been well defined. Briefly, addition of oligosaccharides1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (215) 923-7144. E-mail: block@lac.jci.tju.edu. to asparagine residues of polypeptides occurs cotransla-
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FIG. 1. The N-linked glycosylation pathway in eukaryotes and secretion of HBV from cells treated with inhibitors of the glycosylation pathway.
(A) The pathway of processing of N-glycan, within the endoplasmic reticulum, is shown. Solid circles (glucose), Dotted squares (mannose), and
triangles (N-acetylglucosamine). Processing progresses from left to right, with the various enzymes shown. The point at which the inhibitors used
in this study act is also presented with Tun (tunicamycin) and other abbreviations as explained in the text. P-pdol (dolichol phosphate). Derived
from (30). (B) Secretion of HBV from HepG2.2.15 cells treated with inhibitors of either glycosylation or glycolipid synthesis. HepG2.2.15 cells were
left untreated (‘‘no drug’’) or NB-DNJ (lane ‘‘NB’’, 1000 mg/ml); NB-DGJ (330 mg/ml), DMJ (330 mg/ml or 1000 mg/ml in ‘‘DMJ*’’), or DNJ (700 mg/ml), for
3 days. After this incubation, HBV DNA from the culture medium of approximately 107 cells was isolated, resolved in agarose gels, transferred to
H/ bond membrane and hybridized to radioactive HBV-specific probe, as in (3). An autoradiographic image is presented. Molecular weight markers,
based upon HindIII digested l DNA and EcoRI-digested HBV containing plasmids, are also presented. Arrows indicate mobility of HBV viral DNA.
tionally in the ER and follows a highly ordered sequence butyldeoxynojirimycin (NB-DNJ) (3). Since NB-DNJ is an
inhibitor of ER glucosidase I (Ref. 9 and Fig. 1A), it wasof enzymatic reactions (see 8). The location of the en-
zymes mediating N-glycan addition and subsequent pro- hypothesized that the removal of glucose from nascent
N-glycan is necessary for virion secretion. However, NB-cessing is spatially characteristic, as shown in Fig. 1A.
With specific enzyme inhibitors, the pathway can be bio- DNJ has recently been shown to also inhibit glycolipid
synthesis (24). Thus, it was possible that the preventionchemically dissected by interrupting the processing path-
way at discreet enzymatic steps. Thus, the properties of of virion secretion by NB-DNJ was due to the inhibition
of glycolipid synthesis and unrelated to an effect uponglycoproteins bearing oligosaccharides of different
stages of maturity can be studied. This approach was glucosidase I. To distinguish between these two possibil-
ities, the ability of HepG2.2.15 cells to secrete HBV inused to assess which steps, if any, in the glycosylation
processing pathway are important for virus and subviral the presence of either deoxygalactonojirimycin (NB-DGJ)
or deoxynojirimycin (DNJ) was tested. NB-DGJ has theparticle formation and secretion.
The ability of cells to secrete virions and subviral parti- same glycolipid synthesis inhibiting properties as NB-
DNJ, without a measurable affect upon glucosidase I (23).cles was determined as a function of treatment with
different inhibitors of the glycosylation pathway. On the other hand, DNJ inhibits glucosidases I and II,
without a detectable effect upon glycolipid synthesis (seeHepG2.2.15 cells are a stably transfected HepG2 (human
hepatoblastoma) cell line which persistently secrete HBV 8, 22).
Therefore, after 3 days of incubation of HepG2.2.15(27). We have previously shown that the secretion of
DNA containing HBV particles by HepG2.2.15, as well as cells with NB-DNJ, NB-DGJ, or DNJ at concentrations
known to inhibit their target enzymes, the amount of HBVexogenously infected HepG2 cells, is prevented by n-
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TABLE 1
Viability of 2.2.15 Cells Following Incubation with Inhibitors
MTT activityc
Inhibitora Trypan blueb (U/mg) Albumind (%) Antitrypsine (%)
None 87% { 1% (310) 0.685 { 0.08 100 100
NB-DNJ 83% { 5% (440) 0.680 { 0.05 130 40
DNJ 75% (450) N.D.f N.D. N.D.
DMJ 88% (450) 0.600 { 0.10 105 110
Tunicamycin [5] 89% { 5% (280) 0.650 { 0.04 100 20
Tunicamycin [10] 80% { 10% (300) 0.631 { 0.05 100 N.D.
Tunicamycin* [5] N.D. 0.570 { 0.03 N.D. N.D.
10% ethanolg 0% { 0 (230) 0.071 { 0.01 N.D. N.D.
a HepG2.2.15 cells, grown to confluency, were incubated for 3 days in the absence (none) or presence of NB-DNJ (750 mg/ml), DNJ (650 mg/ml),
DMJ (1000 mg/ml), or Tunicamycin (5 or 10 mg/ml, as indicated in brackets [ ]). After 3 days (or, in the case of 10% ethanol, one day) of culture in
the absence or presence of the indicated inhibitor, cells were tested for viability. The samples described in the row with tunicamycin (*) were
incubated with 5 mg/ml tunicamycin for 7 days. All chemicals were from Sigma, Inc. (St. Louis, Mo.), with the exception of NBDNJ (gift of Monsanto,
Inc.) and DGJ (T. Butters, Glycobiology Institute).
b Cells were incubated with 0.5% trypan blue at room temperature for 5 min and counted under light microscopy. % value refers to the fraction
of the culture resisting trypan blue, with the numbers in parentheses as the total number of cells counted.
c Cells were subjected to a standard and commercial MTT assay with values in units of activity per microgram of protein (18). OD values read
at 590 nm.
d Cells were incubated at 377 for 30 min with 100 mCi/ml [35S]methionine and chased with nonradiactive medium for 4 h, followed by immunoprecipi-
tation of the culture medium with antialbumin serum, resolution in SDS–PAGE and autoradiography as in (2). The amount of albumin secreted by
untreated cultures is assumed to be 100%.
e Cells were labeled with [35S]methionine as above, followed by immunoprecipitation with mAb specific for human antitrypsin and SDS–PAGE.
The amount of antitrypsin secreted from untreated cultures is assumed to be 100%.
f N.D., not done.
g The background levels of MTT from ‘‘dead cells’’ were determined by performing MTT assays on cells incubated with 10% ethanol, overnight.
in the culture medium was determined. Briefly, culture a decrease in the rate of secretion of alpha 1 antitrypsin,
as detected by resolution in SDS–polyacrylamide gelsmedium was centrifuged through a sucrose cushion and
the HBV DNA was extracted by phenol/chloroform, fol- (Table 1). This is a characteristic affect of glucosidase I
inhibition in HepG2 cells (20). The ability of NB-DGJ tolowing protease digestion. Recovered DNA was resolved
by agarose gel electrophoresis and Southern blot hybrid- inhibit glycolipid synthesis in these cells at the concen-
trations used was assessed by other methods (work inization (as in Ref. 3). The results are shown in Fig. 1B.
Both relaxed circular and linear forms of HBV DNA are progress).
Having determined that processing by ER glucosidasedetected in virions isolated from the medium of untreated
HepG2.2.15 cells (lane: no drug). Compared with control I was necessary for virion secretion, it was of interest to
know if steps later in the processing pathway were alsocultures which did not receive inhibitors, NB-DNJ pre-
vented the secretion of more than 95% of the detectable essential for secretion. After removal of glucose residues
by glucosidases I and II, N-linked oligosaccharides onDNA containing virus, as determined by densitometry of
the HBV-specific bands (Fig. 1B, compare lane NB with polypeptides are further processed by ER and Golgi man-
nosidases (see 16). These mannosidases can be inhib-no drug). NB-DGJ had little reproducible inhibitory effect
upon secretion (Fig. 1B, lane: DGJ). DNJ, however, had ited, within the cell, by noncytotoxic concentrations of
deoxymannojirimycin (DMJ). Cells treated with effectivean inhibitory effect similar to that seen with NB-DNJ (Fig.
1B, lane DNJ). These results suggest that the anti-HBV concentrations of DMJ, therefore, synthesize glycopro-
teins bearing high mannose structures (8). To determinesecretory properties of NB-DNJ are attributable to inhibi-
tion of glucosidase I and not glycolipid synthesis. if mannosidase function was necessary for HBV secre-
tion, the amount of HBV in medium of HepG2.2.15 cellsNote that the viability of cultures treated with the indi-
cated concentrations of imino sugar inhibitors were in- incubated for 3 days with concentrations of DMJ shown
to inhibit glycan processing was compared with that fromdistinguishable from those left untreated, as determined
by (i) trypan blue dye exclusion analysis and (ii) ability untreated cultures. The results of a typical experiment
are shown in Fig. 1B. In the experiment presented, twoto secrete metabolically labeled albumin (Table 1). There-
fore, the effect of DNJ and NB-DNJ upon HBV secretion concentrations of DMJ were used. Clearly, at either con-
centration (330 or 1000 mg/ml DMJ), untreated and DMJ-was not the result of nonspecific cytotoxicity. In addition,
these concentrations of NB-DNJ and DNJ were shown to treated cultures secreted similar amounts of HBV (Com-
pare lanes DMJ, DMJ*, and no drug, Fig. 1B).inhibit glycosylation processing by their ability to cause
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The ability of DMJ to inhibit glycan processing was
confirmed by examination of the electrophoretic mobility
(not shown) and relative abundance (Table 1) of the gly-
coprotein alpha 1 antitrypsin from untreated and DMJ-
treated cells. Inhibition of glycan processing causes a
characteristic increase in the molecular weight of anti-
trypsin, because of the retention of the high mannose
glycan (20) without a reduction in the amount of antitryp-
sin secreted. Proteins from DMJ-treated cells exhibit the
expected gel mobility alterations, consistent with the inhi-
bition of mannosidase (not shown) without a significant
effect upon secretion (Table 1). Finally, the concentra-
tions of DMJ used in these studies were shown to have
no significant effect upon cell viability, as determined
by (i) trypan blue staining and (ii) secretion of albumin
(Table 1).
Therefore, it is concluded that although glucosidase
function is necessary for HBV secretion, once that step
is passed, an irreversible commitment to virion secretion
is made. Hence, mannosidase action is dispensable for
the virion secretory process.
Having identified the last step in the glycosylation
pathway necessary for virion secretion (glucosidase
function), it was of interest to know if it is the addition of
glycan, itself, which is necessary (see Fig. 1A). Addition
of N-glycan to polypeptides is effectively inhibited by tuni-
camycin, a nucleoside (UDP-GlcNAc) analog which inhib-
its the formation of GlcNAc-PP-dolicol, the first step of
the N-glycosylation pathway (7). Therefore, the possibility
that glycosylation, itself, is necessary for virion secretion
was tested by measuring the amount of HBV in the me-
dium of cells incubated with varying concentrations of
tunicamycin. Since tunicamycin is more cytotoxic than
are the iminosugar inhibitors used in this study (unpub-FIG. 2. Tunicamycin prevents the appearance of envelope antigen
lished observation), incubation was performed for only 1containing HBV DNA in the culture medium. (A) PCR amplification of
HBV DNA secreted from HepG2.2.15 cells following incubation with day and the viability of the cells was monitored, as de-
various concentrations of tunicamycin. Briefly, HepG2.2.15 cells were scribed below.
incubated in the absence or presence of the indicated amount (mg/ml) Figure 2A shows an analysis of HBV secreted fromof tunicamycin for 1 day. Approximately 1.0 ml of culture medium from
cells in the absence or presence of tunicamycin treat-106 HepG2.2.15 cells was incubated with an amount of monoclonal
ment. Briefly, HBV DNA containing particles present inantibody determined to precipitate the maximum amount of HBV (not
shown). mAbs were (as shown in the figure): aS, C20-02 (gift of W. the culture medium from cells treated for 1 day, with
Gerlich, Giessen, Germany); aM/preS2, T (21); and aL/preS1, MA 18/ either no drug or 2, 5, and 10 mg/ml tunicamycin were
7 (15). After 2 hr of incubation at 377, 30 ml of protein A agarose beads immunoprecipitated with mAb specific for either L, M, orwere added and incubation continued for 1 hr, 47. Immunocomplexes
S HBsAg (see Fig. 2, legend). The HBV DNA present inwere sedimented and washed twice in 0.5% Tween 20/PBS, twice in
the immunoprecipitates was detected by a PCR, which0.1% Tween 20/PBS, and once in PBS. The final pellet was resuspended
in 15 ml 1.0% NP-40, 1% b-mercaptoethanol, and heated to 957 for 10 could detect as few as 1000 HBV genomes and was
min. PCR was performed in a Perkin–Elmer thermocycler with primer linear over two logs of HBV DNA (Fig. 2B). The PCR
sets 158 and 159 (synthesized by the Jefferson Cancer Institute oligonu- approach permitted the analysis of very small cell culturecleotide facility), where 158 is from nucleotides (nt) 2247 to 2317 (AGA
volumes as well as an extremely sensitive test of theCCA CCA AAT GCC CCT ATC) and 159 is from nt 2834 to 2814 (TTC
CCA AGA ATA TGG TGA CCC), where the EcoRI site is nucleotide 1.
These primers are from regions conserved for all known HBV DNA
sequences. Reaction conditions were: 1 cycle of 3 min at 947, 30 cycles HBV virion DNA derived from human serum as in (15) and were sub-
of 1 min at 947, 1 min at 557, 2 min at 727, and a final cycle of 4 min jected to a PCR using the same primers and incubations as in (A), and
at 727. PCR products were resolved by electrophoresis through 1.5% the amplified product was resolved in agarose gels and quantified by
agarose gels and visualized by ethidium bromide staining and the densitometry. Genome copy number was based upon the assumption
photograph is shown. (B) Linearity and sensitivity of the PCR in the that 1 pg of DNA derived from virions equals 3 1 105 genomes. In both
detection of HBV DNA. Samples containing the indicated amounts of (A) and (B), the expected 538 base pairs (bp) product is indicated.
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HBV-specific polypeptides derived from subviral particles
secreted from HepG2.2.15 cells following 1 day of tuni-
camycin treatment. Clearly, under the conditions used
here, HepG2.2.15 cells treated with tunicamycin still effi-
ciently secreted HBV subviral particles. Moreover, the
envelope antigens within those particles migrated with
a mobility suggesting they were devoid of glycosylation.
These results are consistent with reports that show sub-
viral particles of HBsAg were secreted from cells treated
with tunicamycin (25, 28). Note that the immunoblot anal-
ysis also confirms that the recognition of epitopes by two
of the mAbs used in this study is not dependent upon
the glycosylation status of the antigen (Fig. 3). The glyco-
sylation independence of the preS2-specific mAb (T) has
also been observed (X. Lu, unpublished observation and
21). Thus, the inability to immunoprecipitate HBV DNA in
the medium of HepG2.2.15 cells following tunicamycin
treatment using these three antibodies is not due to the
failure of the antibodies to recognize unglycosylated
antigen.
Therefore, this study has provided a detailed analysis
of the steps in the glycosylation pathway which are neces-
sary for HBV virion secretion from cells in culture. NB-DNJ
was shown in previous work to be a potent inhibitor of
virion secretion (3). However, since NB-DNJ inhibits two
distinct intracellular glycosylation pathways (glycolipid
synthesis and oligosaccharide processing), it was not
clear which pathway was the target for the anti-HBV secre-FIG. 3. Immunoblot analysis of HBV envelope antigens produced by
2.2.15 cells in the presence and absence of tunicamycin. 107 tory mechanism. These two pathways can be dissected
HepG2.2.15 cells were incubated with the indicated concentration of by selective inhibition using a new sugar analogue, NB-
tunicamycin (mg/ml). After 1 day, subviral particles were sedimented
DGJ, which only targets glycolipid synthesis (24). NB-DGJfrom the culture medium through sucrose cushions, resolved in 13%
was shown to have no detectable effect upon HBV secre-SDS–PAGEs, and transferred to immobilon membrane (Millipore, Inc.)
tion from HepG2.2.15 cells. On the other hand, DNJ, whichas in (3). The membrane was probed with mouse mAb specific to either
L (A; mAb MA 18/7) or S (B; mAb H166) HBV envelope antigen, followed inhibits glucosidase enzymes without effecting glycolipid
by incubation with alkaline phosphatase-conjugated rabbit anti-mouse synthesis, had an anti-HBV secretory activity similar to
serum. Immunocomplexes were detected by incubation with devel-
that of NB-DNJ. Thus, it is concluded that NB-DNJ preventsoping solution and a photograph of the reaction is shown. Arrows
HBV secretion by inhibiting ER glucosidases.indicate the position of glycosylated (gL) and unglycosylated (L) L
This finding raised the issue of the role of glycosylationHBsAg (in A) and glycosylated (gS) and unglycosylated (S) S HBsAg
(in B). MA 18/7 is described in Heerman and H166 is a gift from Profes- and glycan processing in the egress of HBV and caused
sor W. Gerlich (Giessen, Germany). us to examine which steps in the pathway were essential
and which were dispensable. Since tunicamycin pre-
vented the appearance of enveloped viral DNA in theeffect of the drug’s impact. Figure 2A shows that HBV
DNA can be efficiently immunoprecipitated from the me- medium, but DMJ had no effect, it is concluded that: (i)
N-glycosylation is necessary but (ii) once glycoproteinsdium of cells using either mAb aS (C20-02, Ref. 15),
apreS2 (T, Ref. 21) or apreS1 (MA 18/7, Ref. 15). By pass the glucosidase step, there is a ‘‘commitment’’ to
virion secretion. This lack of a requirement of Golgi en-comparison to the standard curve shown in Fig. 2B, aS,
apreS2, and apreS1 precipitated 7.8 1 104, 1.06 1 105, zyme-mediated complex carbohydrate formation for se-
cretion is not unprecedented. Indeed, many glycopro-and 6.7 1 104 HBV genomes, respectively, from 1 ml of
106 HepG2.2.15 cells which had received no tunicamycin. teins can apparently be secreted with N-linked glycan
that is noncomplex and as a high mannose structureTwo and five mg/ml of tunicamycin prevented the secre-
tion of 97 and 100%, respectively, of the appearance of (e.g., 22, 24). The reason that glycoproteins, in general,
and HBV envelope antigens, in particular, are processedimmunoprecipitable HBV in the medium following only 1
day of treatment. into complex oligosaccharides remains unknown and
may relate to extracellular functions such as receptorThe inhibition of secretion mediated by tunicamycin
was selective for virions and did not affect subviral parti- binding or particle stability.
The requirement of glucosidase processing for virioncle secretion. Figure 3 shows immunoblot analysis of
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